Cro Amaris Clinical Completes USFDA Audit With Nil Observations
24/09/2021 08:03
Sept 24 (Reuters) - Caplin Point Laboratories Ltd CAPL.NS :
* CAPLIN POINT LABORATORIES LTD - APLIN POINT'S CRO AMARIS
CLINICAL COMPLETES USFDA AUDIT WITH NIL OBSERVATIONS
* CAPLIN POINT LABORATORIES SHARES UP 2.4% IN MID-DAY
TRADING
Source text for Eikon: ID:nBSE2sFxn9
Further company coverage: CAPL.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Caplin Point Laboratories
See all newsBrief: Caplin Point Laboratories Says US FDA Completes Unannounced Inspection Of Caplin Steriles Gummidipoondi Facility
Brief: Caplin Point Laboratories March-Quarter Consol Net Profit 1.7 Bln Rupees
Brief: Caplin Point Laboratories Unit Receives Final USFDA Approval For ANDA Potassium Phosphates Injection
Brief: Caplin Point Laboratories Says Unit Receives USFDA Approval For Sodium Phosphates Injection
Brief: Caplin Point Laboratories Dec-Quarter Consol Net Profit 1.64 Billion Rupees